With a strong clinical-phase pipeline, Agenus harnesses a combination of proprietary antibody platforms, including Retrocyte Display™ and SECANT®, and innovative mobile therapy approaches, positioning by itself like a key contributor from the biotechnology and immunotherapy arena.These built-in technologies enable for the event of each solitary-